NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
Country Total |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 1757 | 1.1% | 661 | 0.4% | 259 | 0.2% | 11 | 0.0% | 10 | 0.0% | 82 | 0.1% | 150658 | 98.2% | 153438 | 100.0% |
ASCUS | 4165 | 24.3% | 3642 | 21.2% | 1707 | 9.9% | 48 | 0.3% | 24 | 0.1% | 256 | 1.5% | 7322 | 42.7% | 17164 | 100.0% |
LSIL | 1670 | 20.0% | 2501 | 30.0% | 1449 | 17.4% | 12 | 0.1% | 11 | 0.1% | 138 | 1.7% | 2552 | 30.6% | 8333 | 100.0% |
Atypical glandular cells/AGC | 84 | 25.0% | 53 | 15.8% | 81 | 24.1% | 59 | 17.6% | 27 | 8.0% | 8 | 2.4% | 24 | 7.1% | 336 | 100.0% |
Unclear atypia | 35 | 26.5% | 20 | 15.2% | 50 | 37.9% | 6 | 4.5% | 6 | 4.5% | 4 | 3.0% | 11 | 8.3% | 132 | 100.0% |
ASC-H | 204 | 14.1% | 255 | 17.6% | 862 | 59.7% | 16 | 1.1% | 26 | 1.8% | 9 | 0.6% | 73 | 5.1% | 1445 | 100.0% |
HSIL | 113 | 5.6% | 207 | 10.3% | 1471 | 73.0% | 36 | 1.8% | 62 | 3.1% | 11 | 0.5% | 115 | 5.7% | 2015 | 100.0% |
Suspected Adenocarcinom | 2 | 3.4% | 4 | 6.9% | 5 | 8.6% | 25 | 43.1% | 13 | 22.4% | . | . | 9 | 15.5% | 58 | 100.0% |
Malignant tumor with unclear origin | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | 1 | 100.0% |
Squamous cell cancer | . | . | . | . | 10 | 58.8% | . | . | 6 | 35.3% | . | . | 1 | 5.9% | 17 | 100.0% |
Totalt | 8030 | 4.4% | 7343 | 4.0% | 5895 | 3.2% | 213 | 0.1% | 185 | 0.1% | 508 | 0.3% | 160765 | 87.9% | 182939 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M69760, M80009, M80413, M80703, M80706, M81403, M82003, M85603 |